Previous 10 | Next 10 |
Verve Therapeutics ( NASDAQ: VERV ) said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) clearance its application to start a trial of its gene editing medicine VERVE-101 to treat patients with heterozygous familial hyperchol...
CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisa...
Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn. For further details see: Verve Therapeutics: Cathie Wood Adds To ARKK
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a difficult year for Cathie Wood stocks and exchange-traded funds, as the ARK Innovation ETF (NYSEARCA: ARKK ) has lost over 50% of its market capitalization. The losses have been driven by suppl...
Summary Today, we put mid-cap biotech concern Beam Therapeutics Inc. in the spotlight for the first time. Beam Therapeutics is advancing its pipeline on a wide front and the stock has had a nice ride over the past few months. However, most of Beam's candidates are very early s...
Verve Therapeutics (NASDAQ: VERV) , a clinical-stage gene-editing company focusing on cardiovascular disease, saw its shares race higher this week by a healthy 17.1%, according to data from S&P Global Intelligence . The biotech's stock jumped this week for three key reasons:...
Stifel has upgraded the gene-editing firm Verve Therapeutics ( NASDAQ: VERV ) to Buy from Neutral, citing the prospects for the biotech's lead product candidate, VERVE-101. The single-course therapy is currently undergoing heart-1, a Phase 1b clinical trial in New Zealand fo...
Shares of Verve Therapeutics are up 13% in late Tuesday afternoon trading following the release of preclinical data on VERVE-201 for a type of genetically high cholesterol (homozygous familial hypercholesterolemia). VERVE-201 is designed to permanently turn off the ANGPTL3 ...
CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination...
Verve Therapeutics press release ( NASDAQ: VERV ): Q2 GAAP EPS of -$0.84 misses by $0.20 . Cash, cash equivalents and marketable securities were $293.6 million as of June 30, 2022, as compared to $360.4 million as of December 31, 2021. For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...